<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3437">
  <stage>Registered</stage>
  <submitdate>12/01/2012</submitdate>
  <approvaldate>12/01/2012</approvaldate>
  <nctid>NCT01514188</nctid>
  <trial_identification>
    <studytitle>Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma</studytitle>
    <scientifictitle>A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>INNO-206-P2-STS-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Soft Tissue Sarcoma</healthcondition>
    <healthcondition>Locally Advanced Soft Tissue Sarcoma</healthcondition>
    <healthcondition>Unresectable Soft Tissue Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - INNO-206
Treatment: drugs - Doxorubicin

Active Comparator: Doxorubicin - 

Experimental: INNO-206 - 


Treatment: drugs: INNO-206
INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles

Treatment: drugs: Doxorubicin
Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival - Progression-free survival (PFS) is defined as the time from enrollment to first documentation of objective tumor progression or to death due to any cause in the absence of previous documentation of objective tumor progression.</outcome>
      <timepoint>Over the duration of the trial, approximately 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Survival is defined as the time from enrollment to date of death. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive.</outcome>
      <timepoint>Approximately 36 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival at 4 and 6 months</outcome>
      <timepoint>Month 4 and 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective overall response rate (ORR) - The overall tumor response rate is defined as the total proportion of subjects who have an objective tumor response (CR + PR).</outcome>
      <timepoint>Approximately 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measures. - Adverse events, Ability to remain on assigned treatment (tolerability), Clinical and laboratory data including physical examinations, vital signs, weight, MUGA/cardiac ultrasound evaluations, ECG results and laboratory test results, Use of concomitant medications</outcome>
      <timepoint>Approximately 24 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age between 15-80 years (US only), and 18-80 (rest of world (ROW)), male or female.

          -  Adjuvant or neoadjuvant chemotherapy (including doxorubicin) allowed if no tumor
             recurrence for at least 12 months since the last measurement, beginning or end of last
             chemotherapy.

          -  Histologically or cytologically confirmed, locally advanced, unresectable, and/or
             metastatic soft tissue sarcoma of intermediate or high grade.

          -  Capable of providing informed consent and complying with trial procedures.

          -  ECOG performance status 0-2.

          -  Life expectancy &gt; 12 weeks.

          -  Measurable tumor lesions according to RECIST 1.1 criteria.

          -  Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
             surgically sterile, or practicing adequate birth control methods) for the duration of
             the study. (Adequate contraception includes: oral contraception, implanted
             contraception, intrauterine device implanted for at least 3 months, or barrier method
             in conjunction with spermicide.)

          -  Women of child bearing potential must have a negative serum or urine pregnancy test at
             the Screening Visit and be non-lactating.

          -  Geographic accessibility to the site that ensures the subject will be able to keep all
             study-related appointments.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior chemotherapy unless for adjuvant or neoadjuvant therapy with no tumor recurrence
             for at least 12 months.

          -  Prior exposure to &gt; 3 cycles or 225 mg/m2 of doxorubicin or Doxil®.

          -  Palliative surgery and/or radiation treatment less than 4 weeks prior to
             Randomization.

          -  Exposure to any investigational agent within 30 days of Randomization.

          -  Current Stage 1 or 2 soft tissue sarcomas.

          -  Current evidence/diagnosis of alveolar soft part sarcoma, chondrosarcoma,
             rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST),
             dermatofibrosarcoma, Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, clear
             cell sarcomas and unresectable low grade liposarcomas.

          -  Central nervous system metastasis

          -  History of other malignancies except cured basal cell carcinoma, superficial bladder
             cancer or carcinoma in situ of the cervix unless documented free of cancer for &gt; 5
             years.

          -  Laboratory values: Screening serum creatinine &gt; 1.5x upper limit of normal (ULN),
             alanine aminotransferase (ALT) &gt; 3 × ULN or &gt;5 × ULN if liver metastases are present,
             total bilirubin &gt; 3 × ULN, absolute neutrophil count &lt; 1,500/mm3, platelet
             concentration &lt; 100,000/mm3, hematocrit level &lt; 25% for females or &lt; 27% for males, or
             coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT],
             International Normalized Ratio [INR]) &gt; 1.5 × ULN, albumin &lt; 2.0 g/dL.

          -  Clinically evident congestive heart failure &gt; class II of the New York Heart
             Association (NYHA) guidelines.

          -  Current, serious, clinically significant cardiac arrhythmias, defined as the existence
             of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

          -  Baseline QTc &gt; 470 msec and/or previous history of QT prolongation while taking other
             medications. Concomitant use of medications associated with a high incidence of QT
             prolongation is not allowed.

          -  History or signs of active coronary artery disease with or without angina pectoris.

          -  Serious myocardial dysfunction defined as scintigraphically (e.g. MUGA, myocardial
             scintigram) or ultrasound determined absolute left ventricular ejection fraction
             (LVEF) &lt; 45% of predicted.

          -  History of HIV infection.

          -  Active, clinically significant serious infection requiring treatment with antibiotics,
             anti-virals or anti-fungals.

          -  Major surgery within 3 weeks prior to Randomization.

          -  Substance abuse or any condition that might interfere with the subject's participation
             in the study or in the evaluation of the study results.

          -  Any condition that is unstable and could jeopardize the subject's participation in the
             study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>105</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Royal North Shore - St. Leonards</hospital>
    <hospital>Epworth HealthCare Clinical Trials and Research Centre - Richmond</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Mount Medical Centre - Perth</hospital>
    <hospital>The Crown Princess Mary Cancer Centre Westmead - Sydney</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode> - Richmond</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode> - Hobart</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode> - Perth</postcode>
    <postcode>2145 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ahmedaba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gujarat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Pune Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tami Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>County Cluj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>County Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Judet Maramures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Republic of Tatarstan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernivtsi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharliv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CytRx</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 2b, randomized, open-label, prospective, multicenter study comparing
      treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or
      unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy
      except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor
      recurrence has occurred for at least 12 months.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01514188</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sant Chawla, M.D.</name>
      <address>Sarcoma Oncology Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>